OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in low- and middle-income countries and identify factors associated with successful outcomes. METHODS: We performed a systematic review and meta-analysis of studies of HCV treatment programmes in low- and middle-income countries. The primary outcome was a sustained virological response (SVR). Factors associated with treatment outcomes were identified by random-effects meta-regression analysis. FINDINGS: The analysis involved data on 12 213 patients included in 93 studies from 17 countries. The overall SVR rate was 52% (95% confidence interval, CI: 48-56). For studies in which patients were predominantly infected with genotype 1 or 4 HCV, the pooled SVR rate was 49% (95% CI: 43-55). This was significantly lower than the rate of 59% (95% CI: 54-64) found in studies in which patients were predominantly infected with other genotypes (P = 0.012). Factors associated with successful outcomes included treatment with pegylated interferon and ribavirin, infection with an HCV genotype other than genotype 1 or 4 and the absence of liver damage or human immunodeficiency virus infection at baseline. No significant difference in the SVR rate was observed between weight-adjusted and fixed-dose ribavirin treatment. Overall, 17% (95% CI: 13-23) of adverse events resulted in treatment interruption or dose modification, but only 4% (95% CI: 3-5) resulted in treatment discontinuation. CONCLUSION: The outcomes of treatment for HCV infection in low- and middle-income countries were similar to those reported in high-income countries.
OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in low- and middle-income countries and identify factors associated with successful outcomes. METHODS: We performed a systematic review and meta-analysis of studies of HCV treatment programmes in low- and middle-income countries. The primary outcome was a sustained virological response (SVR). Factors associated with treatment outcomes were identified by random-effects meta-regression analysis. FINDINGS: The analysis involved data on 12 213 patients included in 93 studies from 17 countries. The overall SVR rate was 52% (95% confidence interval, CI: 48-56). For studies in which patients were predominantly infected with genotype 1 or 4 HCV, the pooled SVR rate was 49% (95% CI: 43-55). This was significantly lower than the rate of 59% (95% CI: 54-64) found in studies in which patients were predominantly infected with other genotypes (P = 0.012). Factors associated with successful outcomes included treatment with pegylated interferon and ribavirin, infection with an HCV genotype other than genotype 1 or 4 and the absence of liver damage or human immunodeficiency virus infection at baseline. No significant difference in the SVR rate was observed between weight-adjusted and fixed-dose ribavirin treatment. Overall, 17% (95% CI: 13-23) of adverse events resulted in treatment interruption or dose modification, but only 4% (95% CI: 3-5) resulted in treatment discontinuation. CONCLUSION: The outcomes of treatment for HCV infection in low- and middle-income countries were similar to those reported in high-income countries.
Authors: C Pramoolsinsap; Y Poovorawan; T Sura; A Theamboonlers; N Busagorn; S Kurathong Journal: Southeast Asian J Trop Med Public Health Date: 1998-09 Impact factor: 0.267
Authors: Paulo Roberto L de Almeida; Angelo A de Mattos; Karine M Amaral; Alberi A Feltrin; Pauline Zamin; Cristiane V Tovo; Paulo D Picon Journal: Hepatogastroenterology Date: 2009 Jan-Feb
Authors: Mahmoud Khattab; Mohammed Eslam; Mohammed Ahmed Sharwae; Mohammed Shatat; Ahmed Ali; Lamia Hamdy Journal: Am J Gastroenterol Date: 2010-03-16 Impact factor: 10.864
Authors: Janaína L Narciso-Schiavon; Fernanda Caruso F Freire; Marcelo Mendes Suarez; Marcus Vinícius O Ferrari; Gustavo Quirino Scanhola; Leonardo de Lucca Schiavon; Roberto J de Carvalho Filho; Maria Lucia G Ferraz; Antonio Eduardo B Silva Journal: Eur J Gastroenterol Hepatol Date: 2009-04 Impact factor: 2.566
Authors: N Laufer; F Bolcic; M J Rolón; A Martinez; R Reynoso; H Pérez; H Salomón; P Cahn; J Quarleri Journal: Antiviral Res Date: 2011-03-02 Impact factor: 5.970
Authors: Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes Journal: Hepatology Date: 2014-07-28 Impact factor: 17.425
Authors: Anna Davies; Kasha P Singh; Zara Shubber; Philipp Ducros; Edward J Mills; Graham Cooke; Nathan Ford Journal: PLoS One Date: 2013-02-05 Impact factor: 3.240